Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry.

Diego F Wyszynski Lydia Demetriou Cheryl Renz Shirin Aliabadi Dragutin Rafailovic Lee P Shulman Myriam Drysdale Keele E Wurst

Published in: Drug safety (2024)

A sizable proportion of sotrovimab-treated participants in the COVID-PR had underlying medical conditions associated with an increased risk of severe COVID-19. None of the assessable SAEs were considered to be related to sotrovimab treatment.

Keyphrases

coronavirus disease
sars cov
preterm birth
healthcare
respiratory syndrome coronavirus
early onset
pregnant women
emergency department
drug induced
combination therapy
adverse drug